Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date

Lignende værker

• Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
  af: Chau V, et al.
  Udgivet: (2020-08-01)
• Combination of pembrolizumab and axitinib: a new gold standard in the first-line therapy for metastatic clear-cell renal-cell carcinoma?
  af: R. A. Gafanov, et al.
  Udgivet: (2020-09-01)
• In Russia, a new indication for pembrolizumab in combination with axitinib in the first-line treatment of patients with advanced renal cell carcinoma has been approved
  af: Article Editorial
  Udgivet: (2019-12-01)
• Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date
  af: Sheng IY, et al.
  Udgivet: (2020-06-01)
• Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date
  af: Sheng, Iris Y, et al.
  Udgivet: (2020)